Tagged with Therapy

Cell & Gene Therapy The cell and gene therapy market was valued at USD 6 billion in 2017 and is projected to exceed USD 35 billion in value by 2026. Moreover, these therapies stand to redefine medical paradigms by providing treatments for previously incurable diseases and usher in a new era of precise and…

Europe A full list of EMA ATMP approvals. Made with Visme Infographic Maker  

Cell & Gene Therapy A full list of the cell and gene therapy products approved by the US FDA. Made with Visme Infographic Maker  

Cell & Gene Therapy A full list of the regenerative medicine products that have been approved by the PMDA, Japan’s drug regulatory body.   Made with Visme Infographic Maker  

Korea Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing clinical trials, and the complementarity of oncolytic virus with other gene therapies such as CAR-T.   Oncolytic virus is not…

Cell & Gene Therapy Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene therapy, spoke to PharmaBoardroom about the pioneering product’s journey to market, what has been learnt along the way, and how his team has worked to assuage concerns…

Cell & Gene Therapy Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe, the work still to be done to get this product to more patients who need it across the continent, and the future of cell and…

Cell & Gene Therapy Deloitte’s Omkar Kawalekar, Hussain Mooraj, and Amit Agarwal examine the evolution and future of cell and gene therapy manufacturing and the areas in which biopharma firms need to invest in order to succeed in this emergent field.   Cell and gene therapies (CGT) are the next evolution of personalized health…

Belgium Ian Wilders of Spain-headquartered micro-immunotherapy specialist Labo’Life discusses the strategic importance of Belgium to the company as the country in which micro-immunotherapy was discovered and where regulation conducive to the introduction of these therapies is increasingly being introduced.   Micro-immunotherapy was the discovery of a Belgian doctor therefore it is…

South Korea South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion in its biopharma and biotech sectors over the next five years, the country’s prominence in the global biopharma landscape will…

Belgium Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes the country a perfect environment for Bone Therapeutics as a biotech company focusing on innovative cell and gene therapy.  …

Morocco Sanaa Sayagh of Roche Morocco shares her commitment to bringing the latest immunotherapies to Moroccan patients through partnerships with health authorities and the Lalla Salma Foundation on creative access programs. Sayagh also touches on how Roche is attempting to make personalised healthcare a reality in Morocco.   Despite the lack…